Biotech News

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

Precision BioSciences (DTIL)Precision BioSciences2026-04-15 11:01 ESTFDA / regulatory

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment - DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to

Precision BioSciences

ARCUS Gene Editing Platform Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material. PBGENE-HBV PBGENE-HBV is a wholly...

Recent company news

DTILPrecision BioSciences2026-08-24 10:01 EST

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

DTILPrecision BioSciences2026-07-31 11:01 EST

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

DTILPrecision BioSciences2026-07-27 11:01 EST

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

DTILPrecision BioSciences2026-07-10 11:01 EST

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DTILPrecision BioSciences2026-06-29 11:01 EST

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

Stock data

Close: 8.85 USD
Market cap: 163.07M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States